These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38592023)

  • 1. Discovery of 2-Amide-3-methylester Thiophenes that Target SARS-CoV-2 Mac1 and Repress Coronavirus Replication, Validating Mac1 as an Antiviral Target.
    Wazir S; Parviainen TAO; Pfannenstiel JJ; Duong MTH; Cluff D; Sowa ST; Galera-Prat A; Ferraris D; Maksimainen MM; Fehr AR; Heiskanen JP; Lehtiö L
    J Med Chem; 2024 Apr; 67(8):6519-6536. PubMed ID: 38592023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of 2-amide-3-methylester thiophenes that target SARS-CoV-2 Mac1 and repress coronavirus replication, validating Mac1 as an anti-viral target.
    Wazir S; Parviainen TAO; Pfannenstiel JJ; Duong MTH; Cluff D; Sowa ST; Galera-Prat A; Ferraris D; Maksimainen MM; Fehr AR; Heiskanen JP; Lehtiö L
    bioRxiv; 2023 Dec; ():. PubMed ID: 38234730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unique Mutations in the Murine Hepatitis Virus Macrodomain Differentially Attenuate Virus Replication, Indicating Multiple Roles for the Macrodomain in Coronavirus Replication.
    Voth LS; O'Connor JJ; Kerr CM; Doerger E; Schwarting N; Sperstad P; Johnson DK; Fehr AR
    J Virol; 2021 Jul; 95(15):e0076621. PubMed ID: 34011547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 Mac1 is required for IFN antagonism and efficient virus replication in cell culture and in mice.
    Alhammad YM; Parthasarathy S; Ghimire R; Kerr CM; O'Connor JJ; Pfannenstiel JJ; Chanda D; Miller CA; Baumlin N; Salathe M; Unckless RL; Zuñiga S; Enjuanes L; More S; Channappanavar R; Fehr AR
    Proc Natl Acad Sci U S A; 2023 Aug; 120(35):e2302083120. PubMed ID: 37607224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting SARS-CoV-2 Nsp3 macrodomain structure with insights from human poly(ADP-ribose) glycohydrolase (PARG) structures with inhibitors.
    Brosey CA; Houl JH; Katsonis P; Balapiti-Modarage LPF; Bommagani S; Arvai A; Moiani D; Bacolla A; Link T; Warden LS; Lichtarge O; Jones DE; Ahmed Z; Tainer JA
    Prog Biophys Mol Biol; 2021 Aug; 163():171-186. PubMed ID: 33636189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PARP12 is required to repress the replication of a Mac1 mutant coronavirus in a cell- and tissue-specific manner.
    Kerr CM; Parthasarathy S; Schwarting N; O'Connor JJ; Pfannenstiel JJ; Giri E; More S; Orozco RC; Fehr AR
    J Virol; 2023 Sep; 97(9):e0088523. PubMed ID: 37695054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 Mac1 is required for IFN antagonism and efficient virus replication in mice.
    Alhammad YM; Parthasarathy S; Ghimire R; O'Connor JJ; Kerr CM; Pfannenstiel JJ; Chanda D; Miller CA; Unckless RL; Zuniga S; Enjuanes L; More S; Channappanavar R; Fehr AR
    bioRxiv; 2023 Apr; ():. PubMed ID: 37066301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutation of a highly conserved isoleucine residue in loop 2 of several β-coronavirus macrodomains indicates that enhanced ADP-ribose binding is detrimental for replication.
    Kerr CM; Pfannenstiel JJ; Alhammad YM; O'Connor JJ; Ghimire R; Shrestha R; Khattabi R; Saenjamsai P; Parthasarathy S; McDonald PR; Gao P; Johnson DK; More S; Roy A; Channappanavar R; Fehr AR
    J Virol; 2024 Oct; ():e0131324. PubMed ID: 39387584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of compounds that inhibit SARS-CoV-2 Mac1-ADP-ribose binding by high-throughput screening.
    Roy A; Alhammad YM; McDonald P; Johnson DK; Zhuo J; Wazir S; Ferraris D; Lehtiö L; Leung AKL; Fehr AR
    Antiviral Res; 2022 Jul; 203():105344. PubMed ID: 35598780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The SARS-CoV-2 Conserved Macrodomain Is a Mono-ADP-Ribosylhydrolase.
    Alhammad YMO; Kashipathy MM; Roy A; Gagné JP; McDonald P; Gao P; Nonfoux L; Battaile KP; Johnson DK; Holmstrom ED; Poirier GG; Lovell S; Fehr AR
    J Virol; 2021 Jan; 95(3):. PubMed ID: 33158944
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Xie S; Cao S; Wu J; Xie Z; Liu YT; Fu W; Zhao Q; Liu L; Yang L; Li J
    J Biomol Struct Dyn; 2024 Jul; 42(10):5229-5237. PubMed ID: 37349935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors.
    Huff S; Kummetha IR; Tiwari SK; Huante MB; Clark AE; Wang S; Bray W; Smith D; Carlin AF; Endsley M; Rana TM
    J Med Chem; 2022 Feb; 65(4):2866-2879. PubMed ID: 34570513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-Throughput Screening and Quantum Mechanics for Identifying Potent Inhibitors Against Mac1 Domain of SARS-CoV-2 Nsp3.
    Selvaraj C; Dinesh DC; Panwar U; Boura E; Singh SK
    IEEE/ACM Trans Comput Biol Bioinform; 2021; 18(4):1262-1270. PubMed ID: 33306471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PARP12 is required to repress the replication of a Mac1 mutant coronavirus in a cell and tissue specific manner.
    Kerr CM; Parthasarathy S; Schwarting N; O'Connor JJ; Giri E; More S; Orozco RC; Fehr AR
    bioRxiv; 2023 Jun; ():. PubMed ID: 37398292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and evaluation of inhibitors of the SARS-CoV-2 nsp3 macrodomain.
    Sherrill LM; Joya EE; Walker A; Roy A; Alhammad YM; Atobatele M; Wazir S; Abbas G; Keane P; Zhuo J; Leung AKL; Johnson DK; Lehtiö L; Fehr AR; Ferraris D
    Bioorg Med Chem; 2022 Aug; 67():116788. PubMed ID: 35597097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An MHV macrodomain mutant predicted to lack ADP-ribose binding activity is severely attenuated, indicating multiple roles for the macrodomain in coronavirus replication.
    Voth LS; O'Connor JJ; Kerr CM; Doerger E; Schwarting N; Sperstad P; Johnson DK; Fehr AR
    bioRxiv; 2021 Mar; ():. PubMed ID: 33821264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-Based Optimization of ML300-Derived, Noncovalent Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus 3CL Protease (SARS-CoV-2 3CL
    Han SH; Goins CM; Arya T; Shin WJ; Maw J; Hooper A; Sonawane DP; Porter MR; Bannister BE; Crouch RD; Lindsey AA; Lakatos G; Martinez SR; Alvarado J; Akers WS; Wang NS; Jung JU; Macdonald JD; Stauffer SR
    J Med Chem; 2022 Feb; 65(4):2880-2904. PubMed ID: 34347470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.
    Rathnayake AD; Zheng J; Kim Y; Perera KD; Mackin S; Meyerholz DK; Kashipathy MM; Battaile KP; Lovell S; Perlman S; Groutas WC; Chang KO
    Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32747425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting SARS-CoV-2 nonstructural protein 3: Function, structure, inhibition, and perspective in drug discovery.
    Li X; Song Y
    Drug Discov Today; 2024 Jan; 29(1):103832. PubMed ID: 37977285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-Throughput Activity Assay for Screening Inhibitors of the SARS-CoV-2 Mac1 Macrodomain.
    Dasovich M; Zhuo J; Goodman JA; Thomas A; McPherson RL; Jayabalan AK; Busa VF; Cheng SJ; Murphy BA; Redinger KR; Alhammad YMO; Fehr AR; Tsukamoto T; Slusher BS; Bosch J; Wei H; Leung AKL
    ACS Chem Biol; 2022 Jan; 17(1):17-23. PubMed ID: 34904435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.